Enlivex Therapeutics Ltd. (ENLV.TA)
ILA 433.2
(5.2%)
ILA 433.2
(5.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -24.31 Million USD | -28.41% |
| 2022 | -18.93 Million USD | 20.34% |
| 2021 | -23.77 Million USD | -228.27% |
| 2020 | -7.24 Million USD | 2.37% |
| 2019 | -7.41 Million USD | -21.59% |
| 2018 | -6.1 Million USD | -3.48% |
| 2017 | -2.08 Million USD | 62.76% |
| 2016 | -2.76 Million USD | -2.39% |
| 2015 | -15.45 Million USD | -118.5% |
| 2014 | -7.07 Million USD | -518.99% |
| 2013 | -1.14 Million USD | -405.75% |
| 2012 | -226 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.56 Million USD | 36.14% |
| 2024 Q2 | -2.82 Million USD | 24.88% |
| 2023 Q2 | -6.43 Million USD | 2.08% |
| 2023 Q1 | -6.57 Million USD | 13.77% |
| 2023 Q3 | -5.41 Million USD | 15.89% |
| 2023 Q4 | -5.89 Million USD | -8.81% |
| 2023 FY | - USD | -28.41% |
| 2022 Q2 | -5.69 Million USD | 8.38% |
| 2022 Q3 | -5.48 Million USD | 3.69% |
| 2022 Q4 | -7.62 Million USD | -39.0% |
| 2022 FY | - USD | 20.34% |
| 2022 Q1 | -6.21 Million USD | 18.89% |
| 2021 Q4 | -7.66 Million USD | -106.74% |
| 2021 FY | - USD | -228.27% |
| 2021 Q3 | -3.7 Million USD | -0.57% |
| 2021 Q2 | -3.68 Million USD | -0.03% |
| 2021 Q1 | -3.68 Million USD | 3.23% |
| 2020 Q1 | -738 Thousand USD | 74.92% |
| 2020 Q4 | -3.8 Million USD | -108.09% |
| 2020 Q3 | -1.83 Million USD | 12.19% |
| 2020 FY | - USD | 2.37% |
| 2020 Q2 | -2.08 Million USD | -182.38% |
| 2019 Q2 | -1.2 Million USD | 46.62% |
| 2019 FY | - USD | -21.59% |
| 2019 Q4 | -2.94 Million USD | -47.1% |
| 2019 Q3 | -2 Million USD | -65.56% |
| 2019 Q1 | -2.26 Million USD | 13.13% |
| 2018 Q4 | -2.6 Million USD | -142.55% |
| 2018 FY | - USD | -3.48% |
| 2018 Q1 | -977 Thousand USD | -66.72% |
| 2018 Q2 | -506 Thousand USD | 48.21% |
| 2018 Q3 | -1.07 Million USD | -112.25% |
| 2017 Q2 | -1.59 Million USD | 39.58% |
| 2017 Q1 | -2.63 Million USD | 14.28% |
| 2017 FY | - USD | 62.76% |
| 2017 Q4 | -586 Thousand USD | 45.64% |
| 2017 Q3 | -1.07 Million USD | 32.29% |
| 2016 Q1 | -4.48 Million USD | 7.05% |
| 2016 Q4 | -3.07 Million USD | 32.76% |
| 2016 Q3 | -4.57 Million USD | -23.07% |
| 2016 Q2 | -3.71 Million USD | 17.19% |
| 2016 FY | - USD | -2.39% |
| 2015 Q3 | -3.58 Million USD | 4.07% |
| 2015 Q2 | -3.73 Million USD | -12.67% |
| 2015 Q4 | -4.82 Million USD | -34.69% |
| 2015 Q1 | -3.31 Million USD | -3.76% |
| 2015 FY | - USD | -118.5% |
| 2014 Q3 | -2.12 Million USD | -91.54% |
| 2014 Q4 | -3.19 Million USD | -50.14% |
| 2014 Q1 | -640 Thousand USD | 17.84% |
| 2014 Q2 | -1.11 Million USD | -73.59% |
| 2014 FY | - USD | -518.99% |
| 2013 Q3 | -192 Thousand USD | -43.28% |
| 2013 FY | - USD | -405.75% |
| 2013 Q2 | -134 Thousand USD | 0.0% |
| 2013 Q4 | -779 Thousand USD | -305.73% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Matricelf Ltd | -11.51 Million ILA | -111.223% |